Replimune Group, Inc. (NASDAQ:REPL) Stock Has Consensus Price Target of $12.00 According to Brokerages

Key Points

• Analysts maintain a “Moderate Buy” consensus on Replimune Group, with six buy ratings, one strong-buy, one hold and two sell ratings. The average 12-month price target is $12.00.
• Insiders sold 79,124 shares worth approximately $1.04 million over the past three months, while institutional investors and hedge funds own 92.53% of the company.
• Replimune shares opened at $13.07, above the consensus target, after the company reported a quarterly loss of $0.72 per share versus the expected $0.69 loss.

Replimune Group, Inc. (NASDAQ:REPL - Get Free Report) has been given an average rating of "Moderate Buy" by the ten ratings firms that are presently covering the stock, MarketBeat reports. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating, six have given a buy rating and one has issued a strong buy rating on the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $12.00.

Several equities analysts recently issued reports on the company. Wedbush upgraded Replimune Group from a "neutral" rating to an "outperform" rating and set a $12.00 price target on the stock in a research report on Friday, August 7th. Wolfe Research raised Replimune Group to an "outperform" rating in a research note on Tuesday, August 4th. Piper Sandler upgraded Replimune Group from a "hold" rating to a "strong-buy" rating in a research report on Friday, July 31st. Cantor Fitzgerald reissued an "overweight" rating on shares of Replimune Group in a research note on Monday, October 5th. Finally, JPMorgan Chase & Co. increased their price objective on Replimune Group from $20.00 to $21.00 and gave the company an "overweight" rating in a research note on Wednesday, August 26th.

Insider Activity

In related news, CFO Emily Hill sold 11,448 shares of the company's stock in a transaction on Monday, August 10th. The shares were sold at an average price of $12.97, for a total transaction of $148,480.56. Following the completion of the sale, the chief financial officer directly owned 225,108 shares in the company, valued at $2,919,650.76. This represents a 4.84% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CAO Andrew Schwendenman sold 7,632 shares of the company's stock in a transaction on Monday, August 10th. The shares were sold at an average price of $12.97, for a total transaction of $98,987.04. Following the sale, the chief accounting officer owned 99,425 shares of the company's stock, valued at $1,289,542.25. This represents a 7.13% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 79,124 shares of company stock valued at $1,038,364 in the last three months. Corporate insiders own 5.40% of the company's stock.

Hedge Funds Weigh In On Replimune Group

Hedge funds have recently modified their holdings of the company. Allworth Financial LP bought a new stake in shares of Replimune Group in the second quarter worth about $62,000. Essential Partners LLC increased its holdings in Replimune Group by 562,400.0% during the 1st quarter. Essential Partners LLC now owns 5,625 shares of the company's stock valued at $43,000 after purchasing an additional 5,624 shares during the period. Legal & General Group Plc purchased a new position in Replimune Group during the 2nd quarter valued at about $85,000. WINTON GROUP Ltd bought a new position in Replimune Group during the 2nd quarter valued at approximately $115,000. Finally, E Fund Management Co. Ltd. bought a new position in Replimune Group during the 2nd quarter valued at approximately $119,000. Hedge funds and other institutional investors own 92.53% of the company's stock.

Replimune Group Stock Down 2.6%

Shares of NASDAQ:REPL opened at $13.07 on Tuesday. The stock's 50-day moving average price is $13.88 and its 200-day moving average price is $9.64. Replimune Group has a 12-month low of $1.50 and a 12-month high of $16.33. The stock has a market capitalization of $1.23 billion, a P/E ratio of -4.15 and a beta of 0.93. The company has a current ratio of 5.23, a quick ratio of 5.23 and a debt-to-equity ratio of 1.00.

Replimune Group (NASDAQ:REPL - Get Free Report) last released its quarterly earnings data on Friday, August 14th. The company reported ($0.72) EPS for the quarter, missing the consensus estimate of ($0.69) by ($0.03). On average, equities analysts anticipate that Replimune Group will post -2.82 earnings per share for the current year.

Replimune Group Company Profile

Replimune Group, Inc is a clinical-stage biotechnology company focused on developing oncolytic immunotherapies for the treatment of cancer. The company's approach uses genetically engineered viruses designed to selectively replicate in tumors, directly destroy cancer cells and stimulate a broader immune response against malignant tissue.

Replimune's lead product candidate is RP1, also known as vusolimogene oderparepvec, an engineered oncolytic herpes simplex virus type 1 intended for use in patients with advanced solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.